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The interactions between stem cells and their surrounding microenvironment are pivotal to determine tissue homeostasis and stem
cell renewal or diﬀerentiation and regeneration in vivo. Ever since they were postulated in 1978, stem cell niches have been
identiﬁed and characterized in many germline and adult tissues. Comprehensive studies over the last decades helped to clarify
the critical components of stem cell niches that include cellular, extracellular, biochemical, molecular, and physical regulators.
This knowledge has direct impact on their inherent regenerative potential. Clinical applications demand readily available cell
sources that, under controlled conditions, provide a speciﬁc therapeutic function. Thus, translational medicine aims at
optimizing in vitro or in vivo the various components and complex architecture of the niche to exploit its therapeutic potential.
Accordingly, the objective is to recreate the natural niche microenvironment during cell therapy process development
and closely comply with the requests of regulatory authorities. In this paper, we review the most recent advances of
translational medicine approaches that target the adult stem cell natural niche microenvironment for regenerative
medicine applications.
1. Introduction: Highlights for the
Translation of the Adult Stem Cell Niche
Concept into Therapeutic Applications
Multipotent stem cells are critical biotherapeutics for
regenerative medicine because of their innate ability to
restore the structure and function of adult damaged tissues
or organs. As a matter of fact, self-renewal, clonogenicity,
and multipotentiality are the main common features of
adult stem cells. In the transition from preclinical studies
to clinical application, however, we should consider a
number of hurdles in manipulating stem cells and imple-
ment clinically oriented approaches to control stem cell
fate and function.
The niche is a highly dynamic microenvironment that
can adapt to physiological or diseased conditions [1, 2]. The
interest in targeting the stem cell niche grows and the
opportunity of its remodeling represents a potential valuable
therapeutic target for regenerative medicine [3–5]. Within
the endogenous niche, multipotent stem cells are thoroughly
connected with their surroundings and receive constant
input which directs their fate. Ex vivo, culture conditions
can thus modify the characteristics of cells towards their fates
and further enhance their regenerative potential. Well-
characterized adult niches vary in size and complexity:
human adult stem cells can reside as individual cells within
niches distributed throughout tissues. In other cases, multi-
ple stem cell clusters are identiﬁed, as in the bulge of hair
follicles or in the forebrain subventricular zone. Temporally
speaking, adult stem cells can occupy a single invariant niche
throughout postnatal life, for example, in the central nervous
system; on the contrary, hematopoietic stem cells constantly
recirculate from one bone marrow compartment to another
and further activate hematopoiesis in extramedullary niches,
such as in the liver and in the spleen in stress conditions, for
instance during hematopoietic malignancies [6, 7]. These
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strategies well comply with the concept of the dynamic innate
regenerative capacity of the human body.
To target the stem cell niche, it might be necessary to
regulate its various components such as cell-to-cell contact,
cell to extracellular matrix interactions, and mechanical and
electrical stimuli in a temporally and spatially regulated
manner [8, 9]. Controlling all the niche components is an
unattainable goal; however, this biological complexity trans-
lates into compelling manufacturing processes for reliable,
quality-assured, and cost-eﬀective products for stem cell-
based therapies [10].
Manufacturing of cell therapy products (CTPs) for
clinical application typically requires challenging steps such
as the speciﬁc deﬁnition of identity, potency, and purity of
each CTP. These deﬁnitions are largely therapy dependent.
Towards this purpose, the US Food and Drug Administra-
tion (FDA) releases the current Good Manufacturing Prac-
tice (cGMP) guidelines and the International Conference
on Harmonisation (ICH) introduces a systematic approach
to process manufacturing and product management based
on scientiﬁc knowledge and risk assessment [2, 11]. Overall,
while developing a robust manufacturing process, it is essen-
tial to identify the critical characteristics to ensure product
quality that are directly linked to its safety and eﬃcacy. Stem
cell expansion may be a critical step to determine CTP
quality. Variability of stem cell identity, potency, and purity
is particularly relevant to CTP manufacturing, and every
attempt is made to mitigate the sources of this variability.
For this very reason, the reagents used in CTPmanufacturing
are constantly improved. Many CTPs, formerly cultured in
animal serum or feeder layers, are now cultured in chemically
deﬁned, xenofree or serum-free, cGMP conditions, with the
speciﬁc purpose of reducing product variability [12, 13]. It
is a critical challenge in current clinical translation to
maintain ex vivo the precise characteristics of an identiﬁed
stem cell and its surrounding microenvironment [14, 15].
In the following sections, we discuss the major chal-
lenges to limit adult stem cell product variability, and we
describe, to the best of our knowledge, the most recent
advances for their clinical translation. In general, we high-
light the fact that “Clearly, fundamental scientiﬁc and
medical questions reside within the niche” [16] to develop
eﬃcacious stem cell therapy products.
2. Mimicking the Natural Physical
Microenvironment: Composition of the
Extracellular Matrix for Clinical Applications
Contact with the extracellular matrix (ECM) and with
other cells represents an important mechanism by which
adult stem cells sense the microenvironment and make
decisions about their fate [17]. The precise design of cellu-
lar biophysical microenvironment is a promising approach
with the purpose of controlling stem cell behavior [18, 19].
Furthermore, the modulation of stem cell fate in vitro
through an artiﬁcial microenvironment may eﬃciently
avoid the need for direct genetic manipulation, which is
more problematic for clinical application. Employing an
artiﬁcial ECM aims at recreating the in vivo three-
dimensional (3D) microenvironment.
Noncellular niches represent the ﬁrst attempt for the
development of deﬁned physical culture conditions. The
most recent advances towards therapeutic application
include the development of synthetic bioinformative sub-
strates designed at the micro- and nanoscale level [20].
Microtopography and nanotopography modulate cell behav-
ior including adhesion, self-renewal, proliferation, and
diﬀerentiation and represent emerging powerful tools. Phys-
ical constraints of their microenvironment, including micro-
and even nanoscale geometric information, are detected by
cells: rigidity, stiﬀness, and geometry of the substrate inﬂu-
ence stem cell behavior [21–23]. These technologies have
been adapted from the microelectronics industry and employ
techniques such as surface micropatterning, chemical
etching, and soft lithography to obtain organized pattern
and regular geometries, microﬂuidics, and nanoscale-
engineered three-dimensional (3D) biomimetic scaﬀolds for
high-throughput studies. Lutolf et al. showed that the 3D
topography of the substrate, in synergy with its deﬁned
matrix composition, can facilitate stem cell diﬀerentiation
and alignment, if clinically needed [24, 25]. Nanoscale,
micropatterned, and highly ﬂexible membranes can be used
to develop retinal pigment epithelium layers for minimally
invasive implantation within the eye [26]. As of today,
nanotopography is equally important as a deﬁned culture
medium formulation in the optimization of stem cell culture
conditions [27–29].
The mechanisms by which topographic information of
the biomimetic niche inﬂuence stem cell behavior are not
completely understood; they appear to involve changes in
cytoskeletal organization and structure, mainly at the level
of integrins in the cellular membrane as a response to the
geometry and size of the ECM. This interaction activates
concomitant intracellular signaling cascades and guides stem
cell behavior [30, 31]. Additionally, deﬁned surfaces such as
synthetic peptides containing the Arg-Gly-Asp (RGD) motif
for cell attachment are still fairly new and represent a suc-
cessful option for cell expansion [32–34].
In general, synthetic peptides and surfaces oﬀer the
advantage of being animal component free (ACF) and are
potentially scalable. Matrigel, a poorly deﬁned complex
ECM isolated from the murine Engelbreth–Holm–Swarm
tumor, would not be the ideal choice for clinical applications
[35, 36]. Recombinant versions of single-ECM proteins, such
as ﬁbronectin and laminin, exist and oﬀer the opportunity of
designing a whole ACF cell environment. However, at pres-
ent, recombinant proteins are still cost prohibitive for large-
scale cell therapy product manufacturing.
Biocompatible hydrogel-based ECMs are employed for
the culture of stem cells. Hydrogels are 3D macromolecule
platforms obtained by the crosslinking of hydrophilic poly-
mers. Collagen, ﬁbrin, hyaluronic acid, alginate, dextran,
chitosan, and agarose are used as components for hydrogels
[37, 38]. However, ﬁne modulation of their mechanical
properties, degradation rate, and reproducibility is a chal-
lenge. Consequently, hydrogels polymerized with synthetic
(chemically deﬁned) peptides such as polylactic-glycolic acid
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(PLGA) or polyethyleneglycol (PEG) are developed [39, 40].
Many biodegradable synthetic hydrogel-based products are
approved for clinical use by the FDA and they are speciﬁcally
designed for each clinical application. These deﬁned biomi-
metic ECMs are eﬀective in creating an adequate microenvi-
ronment for adult stem cells; however, it does not seem that
they are suﬃcient to guarantee long-term maintenance of
stem cells in vitro. Thus, we further analyze the additional
important components of the stem cell niche to proceed to
clinical application.
3. Moving towards Standardization of Cell
Therapy Products: A Chemically
Defined Microenvironment
In vitro, cultured cells are subjected to an environment whose
main components are, together with the substrate, the culture
medium, the atmosphere, and cell-to-cell interactions. Each
of these components participate to the complex network of
signaling pathways that eventually determine stem cell fate
[22, 23]. Stem cell culture is widely employed in basic
research and its optimization produces expanded cells in
clinically relevant numbers [28, 32]. Culture media and their
supplements provide the most fundamental nutrients to cul-
tured cells: essential amino acids, a carbon source (typically
glucose and galactose), basic salts, lipids, metal ions, a buﬀer
system to maintain pH, an iron carrier (e.g., transferrin),
growth factors, or hormones. Media supplements provide
adhesion factors and they favor protection from shear
forces (e.g., through surfactants or albumin). Overall, the
medium and its components mimic as much as possible
the situation in vivo.
A universally optimal culture condition does not exist
because stem cells are all diﬀerent. Stem cell culture parame-
ters are deﬁned for each stem cell type and designed on their
intended therapeutic use [41, 42]. Feeder layers supply
growth factors, cytokines, and other extracellular matrix
components such as leukemia inhibitory factor (LIF), activin,
Wnt, bone morphogenetic proteins (BMPs), insulin-like
growth factor (IGF), laminin, and vitronectin to maintain
an undiﬀerentiated state. These cell culture conditions are
ill deﬁned: Mallon et al. reported that feeder cells show
batch-to-batch variability to maintain human embryonic
stem cell (hESC) self-renewal and limited culture scale-up
[43]. Negative results related to xenotransmission are also
detected in long-term culture [44]. This demonstrates the
unsuitability of cellular feeder layers as a culture component.
Thus, studies on the development of feeder-free, possibly
serum-free, and physicochemically deﬁned culture systems
are strongly encouraged.
Good Cell Culture Practice (GCCP) and Good
Manufacturing Practice (GMP) represent the leading guide-
lines to establish standardized protocols for cell-based ther-
apy and regenerative medicine [45]. As a matter of fact, the
design of fully deﬁned media able to maintain stemness, or
alternatively to induce diﬀerentiation towards well-deﬁned
phenotypes, is a point of major interest for stem cell culture
today. Chemically deﬁned media used for the growth of
Chinese Hamster Ovary (CHO) represent an instructive
lesson from the past.
The advantage of deﬁned media, aside from the desirable
ethical reduction or complete absence of fetal bovine serum
(FBS), is the precise chemical composition which thus
facilitates a controlled culture environment for the selective
growth of cells. Deﬁned culture conditions allow the
establishment and the maintenance of phenotypically well-
deﬁned and karyotipycally stable cells.
Cell culture conditions are further optimized by the
implementation of speciﬁc stem cell supplements, that
is, recombinant growth factors or cytokines. The selec-
tion of the medium additives and their concentrations,
especially the growth factors, is critical since it could
variably aﬀect the cultured cells. Adult stem cells require
ex vivo-speciﬁc growth factors that mimic their native
microenvironment.
Growth factors act as mitogens that stimulate cell prolif-
eration and in some cases are crucial to maintain cell charac-
teristics. The most commonly used growth factors in ACF or
xenofree (XF) media for human adult stem cells include basic
ﬁbroblast growth factor, epidermal growth factor, transform-
ing growth factor-β, vascular endothelial growth factor, and
platelet-derived growth factor [46, 47]. Most of these growth
factors are available as recombinant proteins and are widely
used for cell therapy applications.
The speciﬁcity of growth factors, their concentration, and
synergistic eﬀect play a crucial role in achieving an opti-
mized, cell-speciﬁc, deﬁned culture medium. Notably,
growth factor requirements can be not only cell-type speciﬁc
but also species speciﬁc: LIF supports the expansion of a
mouse but not human ESCs. Secreted molecules, such as
colony-stimulating factor and stem cell factor (Kit ligand),
play important roles in cell survival.
Cell-to-cell interactions involving other classes of mole-
cules are also important: interactions between Eph tyrosine
kinase receptors and their Ephrin transmembrane ligands
regulate adult stem cell proliferation and migration [48].
Eﬃcient stem cell manufacturing in vitro is crucial to
guarantee a long-term therapeutic eﬀect in vivo. This critical
issue increases our knowledge on the ﬁne regulation of stem
cell microenvironment and moves translational research into
eﬀective and more reproducible clinical trials.
4. Bioreactors: 3D Mechanical Force
Mimicking the Controlled Oxygen
Perfusion in Stem Cell Niches
For decades, cells are cultured under an atmospheric oxygen
pressure that is much higher than the one experienced in
their niches in vivo. Cell culture incubators normally preserve
atmospheric partial oxygen pressure (pO2) which is around
150mmHg (21% O2). In vivo, physiological pO2 ranges
between 50 and 5mmHg (7–0.7%). Thus, the term “nor-
moxia” referred to standard cell culture systems does not
refer to physiological conditions. Lowering the pO2 is
beneﬁcial for various adult stem cell types [49]: Wion et al.
reported that bone marrow mesenchymal stem cell
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expansion was more eﬃcient at 2% pO2 [50]. Additionally,
the pO2 found in adult stem cell niches is variable.
The stem cell culture medium is dynamic and changes
rapidly due to the release and/or consumption of numerous
metabolites. For this reason, continuous perfusion of cell
cultures with fresh medium through controlled bioreactors
is considered a valuable option to standardize cell-
manufacturing processes. Bioreactors utilize mechanical
forces to inﬂuence biological processes under closely con-
trolled conditions. They provide spatially homogeneous cell
distribution; deliver physiological relevant concentrations of
oxygen, carbon dioxide, and nutrients in the culture medium;
and provide physical stimuli to regulate stem cell diﬀerentia-
tion and proliferation. In bioreactors, stem cells are expanded
in stirred vessels or on perfused scaﬀolds, and their culture
pH and oxygen values are monitored. This controlled process
is beneﬁcial in terms of stem cell expansion and diﬀerentia-
tion compared to conventional static culture conditions,
although autocrine and paracrine loops might be disturbed
[51]. The implementation of sensitive monitoring systems
and control algorithms is required to increase cell product
reproducibility. Various types of bioreactors exist and are
employed in themanufacturing of stem cell therapy products.
5. Reduction of Animal-Derived Components:
Serum-Free Culture and Its Impact on the
Niche Microenvironment
Serum is a mixture of a large number of components, and its
composition is partly uncharacterized. Slight variations in its
composition inﬂuence key properties of cells because they are
highly sensitive to culture conditions. Thus, serum intro-
duces an unknown variable into the culture system, and this
represents a challenge to generate consistent and quality-
assured cells in clinical-scale production [52, 53].
In cell culture, the use of fetal bovine serum (FBS) as a
medium supplement is most widespread. The major function
of serum in stem cell culture media is to provide multiple ele-
ments that correspond to the in vivo condition: hormonal
factors for cell growth and proliferation transport proteins
that carry hormones, minerals, trace elements (e.g., transfer-
rin), and lipids (e.g., lipoproteins). Additionally, it stabilizes
pH with factors inhibiting proteases (such as α-antitrypsin
or α2-macroglobulin), supplies adhesion molecules of the
extracellular matrix, and contains factors that protect against
shear forces [54, 55].
The critical problems related to the presence of FBS in
stem cell culture are batch-to-batch variability, ﬂuctuating
availability, unexpected cell characteristics, and potential
cytotoxicity of uncharacterized factors [56–58]. Gstrauntha-
ler et al. raised several ethical issues concerning the use and
collection of FBS [59, 60]. Most importantly, the immunoge-
nicity of cells cultured in FBS has proven to be challenging
for their use in therapeutic strategies.
Most regulatory agencies tolerate the use of xenogenic
components in culture media in phase I clinical trials. How-
ever, later phase trials are required to employ serum-free or at
least xenofree media. Mendicino et al. reported recently that
FBS is employed during manufacturing in over 80% of the
investigational new drug (IND) applications for mesenchy-
mal stem cell (MSC) products submitted to the FDA [61].
The concentration of FBS ranges from 2 to 20%, with
10% FBS being the most common concentration. Serum
consumption increases on the average of 10%–15% annu-
ally, which suggests that the demand for serum will soon
exceed the actual availability. Safety concerns represent
sound reasons to search for serum substitutes or serum-
free media [62–64].
The major beneﬁts of establishing serum-free cell culture
systems are in the direction of standardization, that is, limita-
tion of the cell therapy product variability, and elimination of
a potential source of contamination [65, 66]. Of note, serum-
free media are generally more cell speciﬁc.
Adult stem cells cannot survive in the absence of serum-
speciﬁc growth factors as well as other unidentiﬁed factors in
the serum. In serum-free culture, a separate attachment sub-
strate is required. Human plasma ﬁbronectin is a common
adhesion substrate used in serum-free systems [67]. Human
platelet lysates (HPLs) are considered a valuable FBS alterna-
tive for adult stem cell expansion [68]. Platelet granules
contain various growth factors and cytokines that can be
released by freeze/thaw-mediated lysis, sonication, or chem-
ical treatment. Due to the wound healing property of platelets
in vivo, growth factors such as platelet-derived growth factor
(PDGF), transforming growth factor-β (TGF-β), ﬁbroblast
growth factor (FGF), insulin-like growth factor-1 (IGF-1),
platelet-derived epidermal growth factor (EGF), vascular
endothelial growth factor (VEGF), together with attachment
factors (ﬁbronectin and vitronectin), and protease inhibitors
are exploited for their use [69]. However, hPL preparations
are subjected to donor-to-donor variations.
Pooled humanAB serum (HABS) is an additional alterna-
tive: it supports proliferation of humanmesenchymal stromal
cells (hMSCs) and maintains their characteristics throughout
ex vivo expansion [70]. Furthermore, human umbilical cord
blood serum (hUCBS) is a rich source of soluble growth fac-
tors. hUCBS supports the growth, proliferation, and diﬀeren-
tiation of the resident stem cell population in the fetal blood.
Cord blood deﬁnes distinct characteristics in cord blood-
derived stem cells, and this supplement may constitute a
unique microenvironment to support ex vivo culture of adult
stemcells [71].However, thedrawbacksof hUCBSare various,
likewise anyotherblood-derivedalternative toFBS. Ingeneral,
the possibility of contamination from adventitious agents,
lot-to-lot variability, and limitation of collection volumes
remain a challenge. Contamination issues are kept con-
trolled by strict adherence to blood bank quality standards.
To overcome the issue of limited collection availability,
recombinant forms of human serum albumin are commer-
cially available. Recombinant human serum albumin (r-
HSA) is used instead of puriﬁed human serum albumin
(HSA) [72]. r-HSA is structurally identical to HSA but it
is free from viral and prion contamination, and it guaran-
tees high batch-to-batch consistency. Recombinant human
albumin is more likely to be compliant with regulatory
requirements and may serve as an ACF ancillary product
for cell therapy and regenerative medicine applications
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[56, 61]. The major disadvantage is the price, which is
several times higher for r-HSA than for puriﬁed HSA.
A few serum-free media are also commercially available.
Unfortunately, the composition of commercially available
proprietary serum-free media is generally unknown. Manu-
facturers usually do not disclose this information that is often
requested by regulatory authorities in clinical settings.
The process of developing serum-free media or adapting
stem cells to serum-free culture media is complex and time
consuming. However, the development of these deﬁned
media should be encouraged in view of their intended clinical
application. As stem cell therapy industry advances and clin-
ical trials reach their later phases, culture process validation,
scale-up, and quality assurance of critical raw material are
highly requested.
Addressing this need results in signiﬁcant changes to
current culturing technologies for a beneﬁcial shift towards
more qualiﬁed and compelling therapies. Table 1 shows an
overview of the current alternatives for clinical applications.
6. The Cardiac Stem Cell Niche in
Regenerative Medicine
Extracellular matrix (ECM) composition is precisely regu-
lated during normal heart development and its dysregulation
results in structural and functional heart diseases.
The heart is a biomechanical organ in which the mechan-
ical stress on cardiac cells mainly arises from the hemody-
namic load. Dysregulation of either preload in diastole or
afterload in systole contributes to the pathogenesis of
congenital or adult heart disease. The microenvironment of
stem cells in the adult myocardium includes cardiomyocytes,
vasculature, interstitial cells, and extracellular matrix, each of
them representing a potential target to enhance the regener-
ative potential of the heart after injury.
Cardiovascular diseases represent a major public health
priority. Speciﬁcally, patients who suﬀer from myocardial
infarction may encounter adverse remodeling that can ulti-
mately lead to heart failure. Prognosis of patients aﬀected
by heart failure is very poor with 5-year mortality close to
50%. Despite the impressive progress in the clinical treat-
ment of heart failure in recent years, heart transplantation
is still required to avoid death as the result of the inexorable
decline in cardiac function. Nonetheless, the morbidities
associated with heart transplantation and the limited organ
supply demand the development of new stem cell-based
approaches for regenerative medicine [82–84].
The human heart is one of the organs which regenerates
less in the body, or at least, its regenerative potential is clearly
lower than the intestine, liver, bone, or skin [85]. However,
some degree of cardiomyocyte renewal has to be recognized
[86, 87]. Despite the fact that proliferative rates are clearly
small and quite diﬃcult to detect, they raise the question
whether such innate processes could be increased and
employed therapeutically. Given these observations, the
main objective of cardiac regenerative medicine is to replace
damaged heart cells and, therefore, to restore the physiologi-
cal structure and function of the organ [88, 89]. Various
clinical trials employ adult stem cells to regenerate the heart.
The past decade highlighted the most instructive stem cell-
based studies for cardiac diseases. These ﬁrst-generation
adult stem cell therapies for myocardial regeneration were
promising in small animal models but beneﬁcial eﬀects in
humans were far more moderate [90]. Consequently, the
objective of second-generation therapeutic approaches is
the enhancement of cellular properties and survival to restore
the normal function of the myocardium.
Current investigation deals with combinatory approaches
that employ multiple stem cell types. Preconditioning stem
cells in vitrowith growth factors, hypoxic treatment, or antiag-
ing reagents enhances cellular engraftment, survival, and
diﬀerentiation before administration. An example of this
valuable approach involves the “cardiopoietic” guidance of
multipotent adult stem cells: Behfar et al. employed a speciﬁc
cardiogenic cocktail for human mesenchymal stem cells
through manipulation of their culture environment [91].
The authors assessed this approach in the C-CURE trial
(ClinicalTrials.gov Indentiﬁer: NCT00810238) and in the
larger CHART-1 (ClinicalTrials.gov Indentiﬁer: NCT01768702)
clinical trial to treat ischemic heart failure. So far, prelim-
inary results indicate a positive although not statistically
signiﬁcant trend in the treated group.
Engineered scaﬀolds represent 3D myocardial tissue for
adult stem cell culture; this approach includes synthetic
porous scaﬀolds or scaﬀold-free cell sheets to increase cardiac
contractility and output. In an eﬀort to use physicochemi-
cally deﬁned components, recombinant human laminin and
recombinant human ﬁbronectin in our hands (Figure 1,
unpublished results) are used [92].
Complex 3D ECM, including ECM obtained from decel-
lularized hearts, provides a superior microenvironment over
single 2D ECM components with regard to cardiac stem cell
structural organization and function [93–95]. Hydrogels are
an eﬀective alternative to scaﬀolds: they create a synthetic
microenvironment for cells in vitro and are subsequently
administered into the myocardium as a patch or injected into
the damaged region of the heart. 3D bioprinting recently
emerged as an exciting technological advancement for the
construction of 3D myocardial tissue: it is now possible to
print native cardiac tissue or custom-made patient-speciﬁc
devices for cardiovascular diseases.
Exosomes carrying noncoding RNAs are important
players for intercellular communication in the heart. Micro-
RNAs (miRNAs) and long noncoding RNAs (lncRNAs) act
as critical regulators of cardiac development and disease: they
necessitate the implementation into future eﬀorts at mimick-
ing the cardiac microenvironment in vitro. miR-15, miR-17,
mrR-133a, miR-199a, miR-210, miR-451, and miR-499
improve myocardial structure and function after ischemia
or infarction.
Future models may expand into gene therapies: the anal-
ysis of mononuclear polyploid cells naturally occurring in
regenerative tissues represents a more recent approach [96].
7. Conclusions
Several studies performed in the last decades highlight the
importance of the microenvironment in which human
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stem cells grow and maintain their peculiar characteristics.
Various components of the human stem cell niche are
clariﬁed, and the objective of recreating an appropriate
native microenvironment is the current objective of regen-
erative medicine.
Manufacturing human adult stem cells as therapeutics
should preferably be performed in animal component-free
or reduced animal component systems to avoid the risk of
zoonoses. Ideally, the cell culture systems that are engineered
for this purpose will minimize exposure to animal cells and
proteins by using primarily human or recombinant human
components. Furthermore, it is highly desirable to employ
physicochemically deﬁned culture media, possibly devoiding
complex mixtures such as animal or human serum.
We are moving closer to producing stem cell therapy
products that have very limited contact with animal products
and thus are better candidates for use in regenerative thera-
pies. Although many challenges lie ahead in the industrializa-
tion of CTP manufacturing, we ﬁnd much reason for
optimism. Decades of experience with industrial cell line cul-
ture processes lay the foundation of engineering CTPs such
as bioreactor scale-up, analysis of cellular metabolism,
medium design, optimization of expansion strategies, and
process control. Meanwhile, our understanding of how cells
interact with their environment is improving, and controlled
systems that mimic the cellular microenvironment are gener-
ating important data sets which are increasingly focused on
molecular and cellular information. In parallel, our general
understanding of the molecular basis of stem cell states,
including adhesion properties, metabolic needs, clonogeni-
city, and proliferation control, is progressing. Such ﬁndings
emphasize the importance of a multidisciplinary approach
Table 1: A comprehensive overview of the current available alternatives to recreate the stem cell microenvironment in vitro for
clinical applications.
Component of the native stem cell
niche microenvironment
Function in vivo
Corresponding
component in vitro
Most recent alternatives
Extracellular matrix (ECM)
Physical adhesion;
Cell orientation;
Stem cell fate
Scaﬀolds or matrices
(2D or 3D)
Coating substrates
Hydrogels [39, 40];
Synthetic peptides (RGD) [73];
Micro- and nanotopographic biomimetic
scaﬀolds [20, 74]
Chemical microenvironment
Provides fundamental nutrients
(salts, ions, lipids, etc.);
Buﬀering system
Cell culture medium
Cell-type-speciﬁc chemically deﬁned
(serum-free) culture medium [75, 76]
Adhesion factors;
Protection from shear forces;
Cell proliferation
Fetal bovine
serum (FBS)
Human platelet lysates [77];
Human pooled AB serum [78];
Human umbilical cord blood serum [71];
Recombinant human serum albumin [72];
Serum-free (or reduced FBS)
culture systems [79]
Cell proliferation
Feeder cells;
Growth factors
Feeder-free systems [44];
Recombinant human growth factors [80]
Cell metabolism and survival Oxygen
Bioreactor-controlled oxygen
perfusion [51, 81]
10% FBS 5% FBS 3% FBS
0% FBS10% FBS 5% FBS 3% FBS
0% FBS
(a)
(e) (f) (g) (h)
(b) (c) (d)
Figure 1: (a, b, c, d) Human cardiac biopsy-derived stem cells cultured in sequentially optimized serum-free culture medium on recombinant
human ﬁbronectin-coated surface. (e, f, g, h) Control culture of human cardiac biopsy-derived stem cells in commercially available serum-free
proprietary medium (Essential 6™, Gibco) on ﬁbronectin-coated surface. Authors’ unpublished results.
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for the development of engineered products, involving the
connection of many disciplines such as cell and molecular
biology, materials science, biomedical engineering, and
medicine. The global perspective is the implementation of a
comprehensive cell therapy product including a deﬁned
serum-free culture medium, a perfusion system, biosensors,
and micro- or nanoscale-designed scaﬀolds mimicking as
far as possible the niche microenvironment that is known
to modulate stem cell function. The future lies probably in
the development of 3D modular biomimetic systems assem-
bled according to the ﬁnal purpose of the stem cell culture,
for example, stemness maintenance or control of cell diﬀer-
entiation towards clinically relevant cell phenotypes.
This massive development requires time and resources
and may also involve remarkable changes to be implemented
into the original manufacturing process. Additionally, full
characterization of the ﬁnal stem cell product after process
development changes is crucial to verify comparability to
the original product. It is also critical to carefully examine
the quality, safety, and availability of the speciﬁc components
implemented into the system to ensure that the selection
meets the needs for further scale-up of the process and result-
ing therapeutic product.
The future of CTPs relies on the development of
cost-eﬀective technologies for cell manufacturing. Given
the inherent complexity of CTPs and their production
processes, appropriately designed approaches will be
essential in transforming today’s experimental CTPs into
available therapeutics.
The advancement of the knowledge and optimization of
the integral components of the human stem cell niche are
instrumental in this ambitious goal.
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